Krystal Biotech, Inc. (NASDAQ:KRYS) Sees Large Decrease in Short Interest

Krystal Biotech, Inc. (NASDAQ:KRYS) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 2,760,000 shares, a decrease of 13.5% from the February 13th total of 3,190,000 shares. Currently, 11.2% of the company’s stock are short sold. Based on an average daily volume of 278,600 shares, the days-to-cover ratio is presently 9.9 days.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently added to or reduced their stakes in the stock. Entropy Technologies LP purchased a new position in shares of Krystal Biotech during the fourth quarter valued at approximately $548,000. Summit Trail Advisors LLC bought a new stake in Krystal Biotech in the 3rd quarter worth approximately $1,893,000. Swiss National Bank raised its stake in Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after buying an additional 2,900 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after buying an additional 15,545 shares during the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after buying an additional 13,874 shares during the period. 86.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Chardan Capital boosted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Citigroup raised their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Stock Performance

Shares of KRYS traded down $0.60 on Thursday, reaching $188.59. The stock had a trading volume of 16,322 shares, compared to its average volume of 282,983. The firm has a market capitalization of $5.43 billion, a price-to-earnings ratio of 63.25 and a beta of 0.87. The company has a 50-day simple moving average of $165.34 and a 200-day simple moving average of $173.69. Krystal Biotech has a 12-month low of $141.72 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.30 EPS. On average, analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).